Literature DB >> 8375125

Pharmacodynamic modeling of the antihypertensive response to amlodipine.

R Donnelly1, P A Meredith, S H Miller, C A Howie, H L Elliott.   

Abstract

The distinctive pharmacokinetic characteristics of amlodipine, particularly the long half-life, are presumed to translate directly to a prolonged duration of action, but the concentration-effect relationship for the antihypertensive response has not been clearly established. In this study of 12 patients with essential hypertension, treatment with 5 mg amlodipine once daily has been evaluated with use of an integrated pharmacokinetic-pharmacodynamic model to calculate individual patient responsiveness for the decrease in blood pressure per unit change in drug concentration. Amlodipine concentrations were well correlated with the placebo-corrected reductions in blood pressure in individual patients and responsiveness, for example, for erect systolic blood pressure was -3.1 +/- 0.9 mm Hg/ng/ml. By characterizing the concentration-effect relationships in individual patients, this study has confirmed that the plasma concentration-time profile is an appropriate index of the effect-time profile, as reflected by an antihypertensive response that is sustained throughout 24 hours with relatively little trough-to-peak variability.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8375125     DOI: 10.1038/clpt.1993.151

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Trough/peak ratios for antihypertensive agents. The issues in perspective.

Authors:  P A Meredith
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 2.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

3.  Pharmacokinetic-pharmacodynamic model for perindoprilat regional haemodynamic effects in healthy volunteers and in congestive heart failure patients.

Authors:  E Bellissant; J F Giudicelli
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of nifedipine. Implications for the care of the elderly.

Authors:  H L Elliott; P A Meredith
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

Review 5.  Role of a third generation calcium antagonist in the management of hypertension.

Authors:  M Epstein
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Amlodipine poisioning complicated with acute non-cardiogenic pulmonary oedema.

Authors:  Ruairi Hasson; Victoria Mulcahy; Hasan Tahir
Journal:  BMJ Case Rep       Date:  2011-09-04

Review 7.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 8.  Therapeutic Approach to Hypertension Urgencies and Emergencies in the Emergency Room.

Authors:  Alessandro Maloberti; Giulio Cassano; Nicolò Capsoni; Silvia Gheda; Gloria Magni; Giulia Maria Azin; Massimo Zacchino; Adriano Rossi; Carlo Campanella; Andrea Luigi Roberto Beretta; Andrea Bellone; Cristina Giannattasio
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-05-18

9.  A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.

Authors:  A D Bainbridge; O Herlihy; P A Meredith; H L Elliott
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model.

Authors:  Dwaipayan Mukherjee; Jiuhong Zha; Rajeev M Menon; Mohamad Shebley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-09       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.